MXPA03005567A - Novel uses of non-peptide bombesin receptor antagonists for treating anxiety and panic disorders. - Google Patents

Novel uses of non-peptide bombesin receptor antagonists for treating anxiety and panic disorders.

Info

Publication number
MXPA03005567A
MXPA03005567A MXPA03005567A MXPA03005567A MXPA03005567A MX PA03005567 A MXPA03005567 A MX PA03005567A MX PA03005567 A MXPA03005567 A MX PA03005567A MX PA03005567 A MXPA03005567 A MX PA03005567A MX PA03005567 A MXPA03005567 A MX PA03005567A
Authority
MX
Mexico
Prior art keywords
receptor antagonists
treating anxiety
panic disorders
bombesin receptor
novel uses
Prior art date
Application number
MXPA03005567A
Other languages
Spanish (es)
Inventor
Denham Pinnock Robert
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of MXPA03005567A publication Critical patent/MXPA03005567A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
MXPA03005567A 2000-12-20 2000-12-20 Novel uses of non-peptide bombesin receptor antagonists for treating anxiety and panic disorders. MXPA03005567A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2000/004915 WO2002049644A1 (en) 2000-12-20 2000-12-20 Novel uses of non-peptide bombesin receptor antagonists for treating anxiety and panic disorders

Publications (1)

Publication Number Publication Date
MXPA03005567A true MXPA03005567A (en) 2003-10-06

Family

ID=9886720

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03005567A MXPA03005567A (en) 2000-12-20 2000-12-20 Novel uses of non-peptide bombesin receptor antagonists for treating anxiety and panic disorders.

Country Status (11)

Country Link
EP (1) EP1343498A1 (en)
KR (1) KR20040007425A (en)
CN (1) CN1461217A (en)
AU (1) AU2001223816A1 (en)
BR (1) BR0017393A (en)
CA (1) CA2432066A1 (en)
HU (1) HUP0302496A2 (en)
IL (1) IL155773A0 (en)
MX (1) MXPA03005567A (en)
PL (1) PL362254A1 (en)
WO (1) WO2002049644A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0403578D0 (en) * 2004-02-18 2004-03-24 Biofocus Discovery Ltd Compounds which interact with the G-protein coupled receptor family
US8101580B2 (en) 2005-04-21 2012-01-24 Astellas Pharma Inc. Therapeutic agent for irritable bowel syndrome
EP2100900A1 (en) * 2008-03-07 2009-09-16 Universitätsspital Basel Bombesin analog peptide antagonist conjugates
CN103463017B (en) * 2013-09-23 2015-11-25 李淑兰 The application of Lycojaponicumin B in preparation treatment pancreatic cancer drug
EP3860635A4 (en) * 2018-10-04 2022-07-06 Rutgers, The State University of New Jersey Methods of reducing type 2 cytokine-mediated inflammation using neuromedin peptides

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU733226B2 (en) * 1996-08-22 2001-05-10 Warner-Lambert Company Non-peptide bombesin receptor antagonists

Also Published As

Publication number Publication date
AU2001223816A1 (en) 2002-07-01
BR0017393A (en) 2004-02-03
EP1343498A1 (en) 2003-09-17
HUP0302496A2 (en) 2003-12-29
IL155773A0 (en) 2003-12-23
WO2002049644A1 (en) 2002-06-27
CA2432066A1 (en) 2002-06-27
PL362254A1 (en) 2004-10-18
KR20040007425A (en) 2004-01-24
CN1461217A (en) 2003-12-10

Similar Documents

Publication Publication Date Title
MXPA03000923A (en) Carboxamide compounds and their use as antagonists of a human 11cby receptor.
IL152775A0 (en) Il-8 receptor antagonists
IL152700A0 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinc receptor antagonists
HUP0202253A3 (en) Selective iglur5 receptor antagonists for the treatment of migraine
DZ3309A1 (en) Il-8 receptor antagonists
IL151431A0 (en) Il-8 receptor antagonists
PL371128A1 (en) Method of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists
EP1274415A4 (en) Il-8 receptor antagonists
MXPA03005567A (en) Novel uses of non-peptide bombesin receptor antagonists for treating anxiety and panic disorders.
GB0028104D0 (en) Bombesin receptor antagonists
AP2002002599A0 (en) Il-8 receptor antagonists
EP1265905A4 (en) Il-8 receptor antagonists
MXPA03004190A (en) Treatment of anxiety disorders.
GB0028146D0 (en) Bombesin receptor antagonists
PL366034A1 (en) Il-8 receptor antagonists
EP1274413A4 (en) Il-8 receptor antagonists
EP1274428A4 (en) Il-8 receptor antagonists
ZA200403530B (en) Chemokine receptor antagonists and methods of use thereof.
IL157102A0 (en) Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
EP1261329A4 (en) Il-8 receptor antagonists
AU2002359706A1 (en) Neuropeptide y5 receptor antagonists for treating depression, anxiety and dementia
IL151434A0 (en) Il-8 receptor antagonists
MXPA03004249A (en) Novel uses of combined selective dopamine d2 receptor antagonists and 5-ht1a.
PL352222A1 (en) Antagonists of the il-8 receptor